EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSUPAG00010002238
Gene Symbol: SCN8A
3 Cross references
274 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSUPAG00010019954
Gene Symbol: SCN9A
3 Cross references
110 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSUPAG00010011241
Gene Symbol: SLC10A2
3 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSUPAG00010006981
Gene Symbol: SLC18A2
1 Cross references
223 Possible Orthologues:

Solute Carrier Family 22 Member 11

Ensembl ID : ENSUPAG00010011593
Gene Symbol: SLC22A11
3 Cross references
885 Possible Orthologues:

Solute Carrier Family 22 Member 12

Ensembl ID : ENSUPAG00010011570
Gene Symbol: SLC22A12
3 Cross references
470 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSUPAG00010005504
Gene Symbol: SLC22A6
1 Cross references
490 Possible Orthologues:

Solute Carrier Family 22 Member 8

Ensembl ID : ENSUPAG00010005520
Gene Symbol: SLC22A8
3 Cross references
310 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSUPAG00010003804
Gene Symbol: SLC29A1
1 Cross references
284 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSUPAG00010015892
Gene Symbol: SLC5A1
3 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSUPAG00010019375
Gene Symbol: SLC5A2
1 Cross references
197 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSUPAG00010023006
Gene Symbol: SLC6A1
1 Cross references
276 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).